Marta Compte

9PUBLICATIONS
69CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsTumour immunologyInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Oct 27, 2025
Simultaneous secretion of a PD-L1 x 4-1BB bispecific antibody improves antileukemic efficacy of STAb-T cells secreting a CD19-specific T-cell engager.

Marina Gómez-Rosel, Laura Rubio-Pérez, Ivana Zagorac

|May 28, 2024
Characterization of a Trispecific PD-L1 Blocking Antibody That Exhibits EGFR-Conditional 4-1BB Agonist Activity.

Laura Rubio-Pérez, Susana Frago, Marta Compte

|Apr 16, 2024
Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses.

Antonio Tapia-Galisteo, Iñigo Sánchez-Rodríguez, Javier Narbona

|Oct 20, 2023
Dendritic Cell-Mediated Cross-Priming by a Bispecific Neutralizing Antibody Boosts Cytotoxic T Cell Responses and Protects Mice against SARS-CoV-2.

Rodrigo Lázaro-Gorines, Patricia Pérez, Ignacio Heras-Murillo

|Apr 28, 2023
A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.

Laura Rubio-Pérez, Rodrigo Lázaro-Gorines, Seandean L Harwood

|Apr 01, 2022
Overcoming CAR-Mediated CD19 Downmodulation and Leukemia Relapse with T Lymphocytes Secreting Anti-CD19 T-cell Engagers.

Belén Blanco, Ángel Ramírez-Fernández, Clara Bueno

Pageof 2

Frequent Collaborators

9 joint publications

Luis Alvarez-Vallina

7 joint publications

Laura Sanz

6 joint publications

Francisco J Blanco

4 joint publications

Laura Rubio-Pérez